Literature DB >> 34687700

ITIH4 is a novel serum biomarker for early gastric cancer diagnosis.

Yingying Sun1, Jie Jin1, Hongyan Jing2, Yingying Lu1, Qingqing Zhu1, Changjuan Shu1, Qinghua Zhang3, Dadao Jing4.   

Abstract

BACKGROUND: Gastric cancer (GC) is one of the most lethal forms of cancer due to the absence of tools for its early detection. Here, we explored critical biomarkers for early diagnosis.
MATERIALS AND METHODS: Key biomarkers in serum from patients with early gastric cancer (EGC) and healthy controls (HCs) were identified via mass spectrometry and the expression of inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) was evaluated using several methods. Furthermore, ITIH4 expression in sera and exosomes from patients with EGC, advanced GC (AGC), low grade intraepithelial neoplasia (LGN), chronic superficial gastritis with Helicobacter pylori infection (Hpi), other systemic malignant tumors (OSTs), and healthy controls was also evaluated.
RESULTS: ITIH4 was identified as a key biomarker in patients with EGC. Its expression level in serum from the EGC group, which showed the highest specificity (94.44%), was significantly higher than those in sera from other GC groups as well as the control. Western blot analysis, immunohistochemical staining, and exosome analysis also confirmed ITIH4 expression in sera from patients with GC, but not in those from healthy individual.
CONCLUSION: ITIH4 is a key biomarker in serum from patients with EGC and has potential as a high value diagnostic marker for EGC.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Advanced gastric cancer; Biomarker; Early gastric cancer; Inter alpha trypsin inhibitor heavy chain 4 (ITIH4); Low grade intraepithelial neoplasia; Mass spectrum

Mesh:

Substances:

Year:  2021        PMID: 34687700     DOI: 10.1016/j.cca.2021.10.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment.

Authors:  Folnetti A Alvarez; Hussein Kaddour; Yuan Lyu; Christina Preece; Jules Cohen; Lea Baer; Alison T Stopeck; Patricia Thompson; Chioma M Okeoma
Journal:  Breast Cancer Res Treat       Date:  2022-09-17       Impact factor: 4.624

Review 2.  Extracellular vesicles and particles impact the systemic landscape of cancer.

Authors:  Serena Lucotti; Candia M Kenific; Haiying Zhang; David Lyden
Journal:  EMBO J       Date:  2022-09-02       Impact factor: 14.012

3.  Systemic Evaluation of the Effect of Diabetes Mellitus on Breast Cancer in a Mouse Model.

Authors:  Nana Wei; Jinmiao Lu; Zhibing Lin; Xiaoyu Wang; Mengmeng Cai; Shengyao Jiang; Xiaoyu Chen; Shilan Zhu; Dong Zhang; Li Cui
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

4.  Serum Antigenome Profiling Reveals Diagnostic Models for Rheumatoid Arthritis.

Authors:  Peng Han; Chao Hou; Xi Zheng; Lulu Cao; Xiaomeng Shi; Xiaohui Zhang; Hua Ye; Hudan Pan; Liang Liu; Tingting Li; Fanlei Hu; Zhanguo Li
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

5.  Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.

Authors:  Stanislav Naryzhny; Natalia Ronzhina; Elena Zorina; Fedor Kabachenko; Nikolay Klopov; Victor Zgoda
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.